Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice.

Antimicrobial Agents and Chemotherapy
J P WongM Kende

Abstract

Polyriboinosinic-polyribocytidylic acid [poly(IC.LC)] was evaluated for its prophylactic and therapeutic efficacies against respiratory influenza A virus infection in mice. Two doses of poly(IC.LC) (1 mg/kg of body weight per dose) administered intranasally within 12 days prior to infection with 10 50% lethal doses of mouse-adapted influenza A/PR/8 virus fully protected the mice against the infection. Determination of virus titers by hemagglutination and plaque assays showed more than a 2-log10 decrease in virus titers in lung homogenates of pretreated mice compared with those in the lungs of the nonpretreated group. Treatment of infected mice with poly(IC.LC) resulted in a modest (40%) survival rate. These results suggest that poly(IC.LC) provides a highly effective prophylaxis against respiratory influenza A virus infection in mice.

Citations

May 21, 2005·Life Sciences·Noé Alvarado-VásquezHeberto Alcázar-Montenegro
Apr 23, 2005·Virus Research·Ryszard MiedzybrodzkiAndrzej Gorski
Dec 30, 2009·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Marina S BoukhvalovaJorge C G Blanco
Aug 29, 2012·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Camila C DiasMarvin J Grubman
Nov 24, 2012·Journal of Virology·L Martínez-GilP Palese
Aug 17, 2005·Journal of Virology·Patricia V AguilarScott C Weaver
May 23, 2006·Emerging Infectious Diseases·Ken Alibek, Ge Liu
Mar 28, 2009·International Journal of Molecular Sciences·Mary E Christopher, Jonathan P Wong
Jan 12, 2013·Veterinary Immunology and Immunopathology·Michael St PaulShayan Sharif
Sep 25, 2015·Future Medicinal Chemistry·Jonathan P Wong
Nov 14, 2006·Brain, Behavior, and Immunity·Tim R TraynorJames M Krueger
May 14, 2005·Antiviral Chemistry & Chemotherapy·Michael Markosian, Robyn M Hyde
Jun 6, 2014·Reproductive Sciences·Renju S RajMark Phillippe
Jul 31, 2020·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sergey A TarasovOleg I Epstein
Dec 10, 2016·Critical Reviews in Microbiology·Beatrice Ellen TyrrellNicole Zitzmann
Sep 25, 2018·Future Virology·Victor CasanovaPeter G Barlow
Aug 16, 2001·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Philip R. Wyde

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.